REVEAL Study Patient Eligibility Criteria

A wide range of patients with PV may be eligible for the REVEAL study.

Key Inclusion Criteria Key Exclusion Criteria
  • Age ≥18 years
  • Diagnosis of PV
  • Willing and able to provide signed informed consent
  • Willing and able to complete patient assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel
  • Under the supervision of a physician for the active management of PV, including but not limited to watchful waiting, ASA 81 mg or greater, antithrombotic therapy, PHL, HU, interferon (recombinant or pegylated busulfan), anagrelide
  • Participation in an active clinical trial in which the study treatment is blinded
  • Life expectancy <6 months
  • Diagnosis of myelofibrosis (MF) (including primary MF or post-PV MF or post-essential thrombocythemia [ET] MF)
  • Diagnosis of acute myelocytic leukemia (AML)
  • Diagnosis of Myelodysplastic Syndrome
  • History of or active plan to proceed to allogeneic hematopoietic stem cell transplant in next 3 months
  • Splenectomy